18 stories mentioning DXCMUpdated just now
Every FINWIRES story that references DXCM, newest first.
DexCom (DXCM) has an average rating of Buy and mean price target of $85.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $83 (from $67), 32x our 2026 EPS estimate, near DXCM's one-year historical forward average of 32.9x and well below its longer-term historical averages to reflect increased competition within the continuous glucose monitoring space, in our view. We lift our 2026 EPS estimate by $0.01 to $2.59 and raise our 2027 estimate by $0.02 to $3.07. We think the addressable market for DXCM is large and far from saturated, but a slower sales growth rate is a concern, which we attribute to market share losses and slow progress in gaining additional insurance coverage. We see the upcoming CONNECT study (for type-2 non-insulin patients) readout as a potentially significant near-term catalyst which may drive enhanced insurance coverage. DXCM sees CMS coverage for all individuals with diabetes by mid-2027, which it believes will increase its addressable U.S. market for type-2 non-insulin intensive diabetes by around 80% to 27M people.
DexCom (DXCM) said Tuesday that two lots of its G7 glucose monitoring sensors designated as scrap were stolen during the destruction process and then sold by third parties.The company said it is working with the US Food and Drug Administration and other authorities to ensure patient safety and investigate the crime, while notifying clients via several communication channels.DexCom said it routinely discards sensors that do not meet standards as part of its quality control process and sends these to a third-party vendor for destruction and recycling. Affected lots are 1725204004 and 1725069002, the company said, adding the issue mainly impacts the US.There have been no reported severe adverse events linked to the stolen products, the company said.Price: $71.72, Change: $-0.38, Percent Change: -0.53%
The Standard & Poor's 500 index rose 0.9% this week, its eighth consecutive week of gains, amid upbeat trading heading into the holiday weekend.The S&P 500 ended Friday's session at 7,473.47, close to the record closing high it reached last week of 7,501.24.This marks the longest weekly winning streak since a nine-week run that ended in December 2023. The index is now up 3.7% for May and has climbed 9.2% in 2026.Government data this week showed US housing starts decreased less than estimated in April amid a jump in multi-family projects, while the single-unit component declined. Separate data from the National Association of Home Builders and Wells Fargo also showed US homebuilder confidence unexpectedly rose in May despite elevated mortgage rates, macro uncertainty and continued affordability challenges.US consumer sentiment, however, declined to a fresh record low in May amid fears that high gasoline prices could erode purchasing power, the University of Michigan said Friday. The main sentiment index tumbled 10% to 44.8 from last month. The consensus in a Bloomberg-compiled poll was for May's print to stay unchanged from a preliminary 48.2 estimate.The health care and utilities sectors led the gainers this week, climbing 3.3% each, followed by a 3% boost in real estate, a 1.9% gain in consumer discretionary and a 1.6% rise in financials. Technology, industrials and materials also edged higher.DexCom (DXCM) had the largest percentage increase in health care, jumping 17% on the week. The company announced the launch of its Dexcom Flex, a continuous glucose monitoring system for adults with Type 2 diabetes who are not using intensive insulin therapy, in Germany.The utilities sector's top gainers included shares of Dominion Energy (D), which unveiled an agreement to merge with NextEra Energy (NEE) in an all-stock deal to create the largest regulated electric utility in the world. Dominion shareholders will receive a 25.5% stake in the combined entity, while NextEra's shareholders will own about 74.5% of the merged company. Dominion's stock climbed 9.6% while NextEra, the only weekly decliner in the sector, lost 5.2%.Communication services fell 1.9%, while consumer staples shed 1% and energy edged down 0.4%.The hardest-hit stocks in communication services included shares of Take-Two Interactive Software (TTWO), which fell 6.1% on the week. The company posted a narrower-than-expected fiscal Q4 loss on higher-than-expected revenue but its fiscal 2027 guidance came in below analysts' mean estimates.Next week will have just four trading days as the US stock market will be closed on Monday for Memorial Day.Earnings reports are expected from companies including Costco Wholesale (COST), Dell Technologies (DELL) and Salesforce (CRM).Economic data will include the April personal consumption expenditures index, which is the Federal Reserve's preferred inflation measure, on Friday. Other reports will include May consumer confidence, April new home sales, and the second revision to Q1 gross domestic product.
US equity indexes slumped as continuing uncertainty over the reopening timeline for the Strait of Hormuz following the China summit spooked investors, sending government bond yields and crude oil futures sharply higher.The Nasdaq Composite dropped 1.4% to 26,225.14, with the S&P 500 down 1.2% to 7,408.5 and the Dow Jones Industrial Average seen lower by 1% to 49,526.1 at the close on Friday.A summit between US President Donald Trump and his Chinese counterpart, Xi Jinping, ended with mixed messages over the reopening of Hormuz, the Wall Street Journal reported. The waterway is the choke point to about a fifth of global crude oil flows, and the impact of its full or partial closure was evident in consumer and wholesale price inflation."The market could be pinning too much hope on the US-China talks yielding some positive results on Iran," ING Bank said in a note. "Some hope that China could exert pressure on Iran to reach a deal with the US, to end the war, and lead to a resumption of energy flows through the Strait of Hormuz."A lack of trust is the biggest obstacle in negotiations to end the war with the US, and Tehran would be open to diplomatic help, particularly from China, to help ease tensions, Iran's foreign minister, Abbas Araghchi, was cited as saying in an Associated Press report. Contradictory messages have "made us reluctant about the real intentions of Americans," he added.Expectations that Hormuz will quickly return to normal maritime traffic levels in June are based on "magical thinking" and underestimate the political and operational barriers to restoring flows, RBC Capital Markets strategists said in a note. The analysts said that oil market disruptions could persist well into the summer demand season.US Treasury yields surged, with the 10-year up 13.8 basis points to 4.60%, the highest in about a year. The two-year advanced 8.9 basis points to 4.08%, the strongest level since February 2025.West Texas Intermediate crude oil futures surged 4.5% to $105.73, and Brent crude futures jumped 3.5% to $109.44.In precious metals, gold futures dropped 3.1% to $4,540.9, and silver futures sank 11% to $76.28 as the impact of higher crude prices has begun to show up in the inflation data. The probability of a 25 basis-point increase in interest rates in December surged to 39% on Friday from 14% a week ago, according to the CME FedWatch tool late Friday. The comparisons for September were 17% from 12%, and, for October, the data showed 27% versus 22%.In economic news, industrial production rebounded by 0.7% in April, above expectations for a 0.3% increase in a Bloomberg-compiled survey, and following an upwardly revised 0.3% decline in March.In company news, DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Shares jumped 6.6%, the top gainer on the S&P 500 and the Nasdaq.
US equity indexes ended lower on Friday as crude oil prices and government bond yields rose, triggering increasing concerns that rising energy costs will spur inflation.* The US war with Iran is nearing its 11th week, and the Strait of Hormuz remains closed to oil tankers.* Industrial production rebounded by 0.7% in April, above expectations for a 0.3% increase in a Bloomberg survey and following an upwardly revised 0.3% decline in March.* June West Texas Intermediate crude oil rose $4.29 to settle at $105.46 per barrel, while July Brent crude, the global benchmark, was last seen up $3.55 at $109.28.* Nvidia (NVDA), Advanced Micro Devices (AMD), Arm Holdings (ARM) and Intel (INTC) shares declined, while ASML Holding (ASML) and STMicroelectronics (STM) also fell after a US-China summit ended without major semiconductor agreements.* DexCom (DXCM) shares rose 6.6%, the top gainer on the S&P 500, after the company set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) dropped 2.4%.In corporate news, Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a note. RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target. Thermo Fisher shares were down 2.3%.Aardvark Therapeutics (AARD) shares fell 32% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG downgraded to neutral from buy.DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Its shares climbed past 6%.ARS Pharmaceuticals (SPRY) shares fell 7% after it posted a wider Q1 loss.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month price target remains $67, 26x our 2026 EPS estimate (raised by $0.09 to $2.58; 2027 estimate raised by $0.06 to $3.05), below DXCM's one-year historical forward average of 33.5x and well below long-term term historical averages to reflect stronger competition within the continuous glucose monitoring space and uncertain insurance coverage and rebate dynamics, in our view. On May 14, DXCM announced a collaboration with activist investment firm Elliott Management, which holds a meaningful equity stake in DCXM (undisclosed amount), based on DXCM's recent press release. Among other potential changes, DXCM is making changes to the composition of its Board of Directors. The company also revealed some details about the upcoming G8 device, which is 50% smaller than the G7 and offers superior performance in terms of speed and real-time sensing capabilities. The G8 is expected to launch toward the end of 2027 or beginning of 2028.
Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index falling 0.9% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 0.8%.The iShares Biotechnology ETF (IBB) dropped 2.5%.In corporate news, Aardvark Therapeutics (AARD) shares fell 31% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG to neutral from buy.DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Its shares climbed past 6%.ARS Pharmaceuticals (SPRY) shares fell nearly 5% after it posted a wider Q1 net loss.Alumis (ALMS) stock was down more than 5% after it reported that its Q1 revenue dropped to $1.7 million from $17.4 million a year earlier.
US equity indexes fell amid a surge in government bond yields and crude oil futures in midday trading on Friday as investors weighed the probability of the Strait of Hormuz reopening in the near term.The Nasdaq Composite fell 1.1% to 26,340.3, while the S&P 500 was down 0.9% to 7,433.7 and the Dow Jones Industrial Average was lower by 0.8% to 49,646.5.All sectors except energy fell. Materials, industrials, utilities, and consumer discretionary led the decliners.A summit between US President Donald Trump and his Chinese counterpart, Xi Jinping, ended with mixed messages, the Wall Street Journal reported. Trump reportedly told Fox News the United States does not need to see the Strait of Hormuz reopen, then told reporters both he and Xi want to see the Iran war end, while also saying Hormuz needs to reopen as soon as possible."The market could be pinning too much hope on the US-China talks yielding some positive results on Iran," ING Bank said in a note. "Some hope that China could exert pressure on Iran to reach a deal with the US, to end the war, and lead to a resumption of energy flows through the Strait of Hormuz."A lack of trust is the biggest obstacle in negotiations to end the war with the US, and Tehran would be open to diplomatic help, particularly from China, to help ease tensions, Iran's foreign minister, Abbas Araghchi, was cited as saying in an Associated Press report. Contradictory messages have "made us reluctant about the real intentions of Americans," he added.Trump said his patience with Iran was running out and that Chinese President Xi Jinping had agreed that Tehran must reopen Hormuz, but China gave no indication it would weigh in, Reuters reported.Expectations that Hormuz will quickly return to normal maritime traffic levels in June are based on "magical thinking" and underestimate the political and operational barriers to restoring flows, RBC Capital Markets strategists said in a note.US Treasury yields surged, with the 10-year up 13 basis points to 4.59%, the highest in about a year. The two-year advanced 9.2 basis points to 4.08%, the strongest level since February 2025.West Texas Intermediate crude oil futures surged 3.8% to $105.02, and Brent crude futures jumped 3.3% to $109.16.In precious metals, gold futures dropped 3% to $4,543.4, and silver futures sank 10% to $76.63.In economic news, industrial production rebounded by 0.7% in April, above expectations for a 0.3% increase in a Bloomberg-compiled survey, and following an upwardly revised 0.3% decline in March.In company news, DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Shares jumped 7.3%, the top gainer on the S&P 500 and the Nasdaq.
DexCom's (DXCM) long-range plan establishes a respectable base case, but significant total addressable market expansion opportunities could allow the company to notably exceed those targets, RBC Capital Markets said.The company's strategic priorities include remaining the premier glucose sensor for diabetics, setting the standard for customer experience in glucose biosensing, and growing international market share, according to the note Friday.DexCom is targeting over 10% revenue growth annually through 2030, gross margins of 67% to 69%, operating margins of 29% to 30%, adjusted EBITDA margins of 36% to 37%, and free cash flow conversion of 80% to 100% with a commitment toward share repurchases. RBC believes the LRP is conservative and positions the company for potential upside ahead, according to the note.RBC expects 2026 revenue of $5.22 billion, gross margins of 63.5%, operating margins of 23.3% and an EPS of $2.56, all within the company's guidance range. It models 2027 revenue and EPS growth of about 11.9% and 18.2%, respectively.RBC kept an outperform rating on DexCom with a price target of $85.Shares of DexCom rose by nearly 7% in Friday trading.Price: $61.70, Change: $+3.88, Percent Change: +6.71%
DexCom (DXCM) has an average rating of overweight and mean price target of $83.08, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $62.64, Change: $+4.82, Percent Change: +8.34%
DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030.Among the targets, initially disclosed at the company's investor day event on Thursday, are a 2030 non-GAAP gross profit margin of 67% to 69%, as well as a 2030 non-GAAP operating profit margin of 29% to 30%, DexCom said.The company expects adjusted earnings before interest, taxes, depreciation, and amortization, or EBITDA, margin of 36% to 37% in 2030.DexCom also said its board has approved a share buyback program of up to $1 billion, with a repurchase period ending no later than June 30, 2027.The board terminated an existing share buyback plan, of which $250 million were available, the company said.Price: $61.50, Change: $+3.68, Percent Change: +6.36%
DexCom (DXCM) has an average rating of overweight and mean price target of $83.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $1 to $67, 26.1x our 2026 EPS estimate (up $0.08 to $2.57; 2027 estimate up $0.06 to $3.05), below DXCM's one-year historical forward average of 34.2x and well below the three-year average of 56.6x, to reflect stronger competition within the continuous glucose monitoring space and uncertain insurance coverage and rebate dynamics, in our view. DXCM recently launched the G7 15-day continuous glucose monitoring (CGM) system in the U.S., which offers users a longer-wear time between devices and increased accuracy, per DXCM. The company expects close to half of its U.S. base to convert to the new device by year-end 2025. We think the addressable market for DXCM is large and far from saturated, but a slower sales growth rate is a concern, which we attribute to market share losses and slow progress in gaining additional insurance coverage approvals.
DexCom (DXCM) added record new patient starts globally in Q1, while the Continuous Glucose Monitoring National Coverage Determination remains the single biggest potential catalyst in 2026 and key driver of future growth, RBC Capital Markets said.The brokerage said in a Thursday note that the US CGM penetration remains only around 30% of covered lives, leaving substantial room for growth even before any incremental coverage expansion.DexCom reiterated its 2026 revenue guidance despite the Q1 beat being largely driven by foreign exchange. It also reaffirmed its 11% to 13% growth outlook, which includes about 100 basis points of contribution from Stelo, RBC said.While investors remain focused on slowing U.S. growth, DexCom reported "very close to a record" new patient starts in the US, with sequential improvement supported by the 15-day G7 rollout and ongoing CGM adoption, the brokerage added.RBC said the company's May 14 Investor Day is a key upcoming catalyst. It estimates 2026 revenue of $5.22 billion and EPS of $2.56, up 12% and 23% year over year, respectively.The firm reiterated its outperform rating and a $85 price target on DexCom.Price: $60.72, Change: $+1.17, Percent Change: +1.96%
DexCom (DXCM) has an average rating of overweight and mean price target of $84.39, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $61.53, Change: $+1.98, Percent Change: +3.32%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DXCM delivered Q1 2026 sales growth of 15% Y/Y (12% organic growth) to $1.192B due to 11% U.S. growth and 26% international growth, with adjusted EPS of $0.56 rising 75% from the prior-year period. Adjusted operating margin expanded 840 bps Y/Y to 22.2%, supported by 600 bps of gross margin improvement to 63.5% on favorable product mix and operational efficiency initiatives. The recent U.S. launch of the G7 15-day CGM system offers users longer wear time between devices and increased accuracy, while new Smart Meal Logging capabilities were rolled out for Stelo OTC product for non-insulin users. Management raised 2026 adjusted operating margin guidance to 23%-23.5%, while reaffirming revenue guidance of $5.16B-$5.25B. With $2.42B in cash and equivalents and negative net debt, DXCM maintains substantial financial flexibility, in our view. We anticipate a more detailed overview of DXCM's long-term strategic outlook at the upcoming Shareholder/Analyst Day on May 27.
